Tianan Fang serves as a Principal Scientist at Bristol Myers Squibb, where he leverages his extensive background in medicinal chemistry to drive innovative drug discovery initiatives. With a robust understanding of drug metabolism, pharmacokinetics (ADME), and toxicology, Tianan plays a pivotal role in the development...
Tianan Fang serves as a Principal Scientist at Bristol Myers Squibb, where he leverages his extensive background in medicinal chemistry to drive innovative drug discovery initiatives. With a robust understanding of drug metabolism, pharmacokinetics (ADME), and toxicology, Tianan plays a pivotal role in the development of novel therapeutics, particularly in the realm of fibrosis. His expertise in structure-based drug design, combined with his proficiency in computer-aided drug design (CADD) and tools like Live Design from Schrodinger, allows him to effectively navigate the complexities of drug development.
Currently, Tianan is leading key projects focused on allosteric inhibitors and pan integrin inhibitors for fibrosis. His work involves conducting structure-activity relationship (SAR) studies to enhance the in-vitro and in-vivo profiles of lead compounds, ensuring they meet the stringent criteria for efficacy and safety. Notably, he has explored the RGD series to identify compounds that exhibit strong potency in co-culture assays while demonstrating favorable pharmacokinetic properties across multiple species, including mouse, dog, and cynomolgus monkey.
Tianan's excellent problem-solving skills enable him to synthesize and interpret multi-parameter data, which is crucial for formulating actionable medicinal chemistry strategies. His leadership experience in supervising both internal teams and contract research organization (CRO) scientists further underscores his capability to drive projects from conception through to successful execution. With a strong foundation in synthetic organic chemistry and a passion for advancing drug discovery, Tianan Fang continues to make significant contributions to the pharmaceutical industry, particularly in the development of therapies that address unmet medical needs.
